The latest clinical trial using results from the COLTHERES project is recruiting patients. The trial involves dacomitinib & the Pfizer MEK inhibitor in KRAS mutant tumors. More information can be found here on the clinicaltrials.gov page
In its first two and half years COLTHERES has achieved effective and clinically relevant results as demonstrated in the graphic below!
A .pdf file of the image can be downloaded here
COLTHERES Partner Horizon Discovery has two posters at the American Association of Cancer Research Annual meeting, April 6-10 2013. They are
COLTHERES partners have been published in the International Journal of Cancer. The article entitled
can be found on the journal website here.
COLTHERES partners Ospedale Niguarda Ca’ Granda and IDIBELL have had a joint paper entitled
The COLTHERES results on Molecular Subtypes Signatures were presented at the 2013 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco. A poster was presented and the abstract was selected for oral presentation and for the ASCO press program. Several websites and newspapers picked up on the story and there have been several follow-up articles about the work.
The poster is available here.
An article on Medscape is available here (A Medscape account is required to view this).
Based on pre-clinical data generated partly within COLTHERES, the following trial has recently been initiated:
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Horizon Discovery presented a poster at EORTC, with results from the COLTHERES project. You can download the poster here.
COLTHERES partners have had a 2nd paper published in Nature, the 2nd in 3 months.
“Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer”
COLTHERES partners have had a paper entitled
published in Clinical Cancer Research.